Golidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomanews2024-06-19T14:40:04+00:00June 19th, 2024|Medical Device News Magazine|
